Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Anticorpii anti-TNFα
Anticorpii anti-TNFα
BII si TNFTNFproductia de TNF de monocite/macrofage locale y rezistenta limfocitelor T din lamina propria la apoptoza
y
Tipuri de Ac anti-TNF antiInfliximab-IFN (Remicade) mAc himerici Iv 5mg/kg S0,2,6,apoi la 8S (remisiune) Adalimumab-ADA (Humira) mAc umani Sc 160mg S0 80mg S2 40mg la 2S
Indicatii si contraindicatii
Cardiac-Insuf.cardiaca NYHA III/IV hemocitopenii Patol.neurologica APP neoplazii (limfom) Hepatita cronica Screening al infectiilor(Cl.difficile, CMV, inf.urinare TB activa/latenta Exam.ginecologic
Investigatii
Istoric medical detaliat Teste in-vitro pt TB (ex.Quantiferon-TB Gold/T-Spot.TB) Rx toracic HBsAg,anti-HBcAb Serologie HIV Hemoleucograma transaminaze
Step up
Top down
1. 2. 3. 4.
Trat. initial cu IFN Studiu randomizat (IFN 5mg/kg+Aza 2.5mg/kg Vs.prednison) Remisiune clinica(simptomatologie): L6: 75% vs. 48% L12: 77% vs.64% Remisiune ulceratii mucoase: L12: 75% vs. 21%
Terapii
Eficacitate
Controlul eficacitatii in studiile clinice util. CDAI (Crohns Disease Activity Index) CDAI70 CDAI100
Metode de evaluare
1.
Scop:steroid-free remission Clinic:-nr.de scaune/zi -nivelul durerii abdominale -simptome extraintestinale -febra -alte medicatii(steroizi) 2.Lab.:CRP,HLG,Transaminaze 3.Imagistic:endoscopie,CT,RMN 4.Status vaccin, test PAP
Complicatii
Infectii-virale, fungice, TB Malignitate:limfom Insuficienta cardiaca congestiva Hemocitopenii Neurologic:demielinizare Cond.inflamatorii si autoimune: Ac ANA si anti-dsDNA:Les Vasculita Glomerulonefrita Reactii la locul de injectie
Sarcina
FDA:cls B (fara efecte adverse in sarcina in studii pe animale+ insuficiente studii umane controlate) y Contraindicate in ultimul trimestru de sarcina(transferul placentar al IgG ) y IFN nu a fost detectat in lapte
y